Farmácia/Notícias da Indústria
Estudo randomizado fase 2 | Segurança e imunogenicidade da vacina da AstraZeneca em crianças de 6-17 anos de idade.
19 Jun, 2022 | 15:37hComentário convidado: Increasing children’s global access to COVID-19 vaccines – The Lancet
Revisão sistemática | Inibidores da Janus quinase para o tratamento de COVID-19.
19 Jun, 2022 | 14:38hJanus kinase inhibitors for the treatment of COVID‐19 – Cochrane Library
Segurança comparativa das vacinas BNT162b2 e mRNA-1273 em uma coorte nacional de veteranos nos EUA.
19 Jun, 2022 | 14:27h
Comentário no Twitter
1/
TODAY: We compared the safety of #COVID19 mRNA vaccines in the largest healthcare system in the US.TAKE-HOME MESSAGE: Both Moderna and Pfizer vaccines are quite safe. If interested in vaccination, you can confidently use whichever one is available.https://t.co/fFIlXwH5Qv
— Miguel Hernán (@_MiguelHernan) June 13, 2022
Recomendação de consenso | Guia para realizar revisões de medicamentos em idosos com câncer.
19 Jun, 2022 | 14:12hConteúdo relacionado: Deprescribing in Palliative Cancer Care – Life
Estudo de coorte | Risco de longo prazo de overdose ou crise de saúde mental após redução de dose e opioides.
19 Jun, 2022 | 14:08hLong-term Risk of Overdose or Mental Health Crisis After Opioid Dose Tapering – JAMA Network Open
Editorial: New Data on Opioid Dose Reduction—Implications for Patient Safety – JAMA Network Open
Comunicado de imprensa: Increased overdose and mental health risks persist two years after opioid dose reduction – UC Davis Center for Healthcare Policy and Research
Diretriz BSH para manejo hematológico de hemorragia de grande volume.
19 Jun, 2022 | 13:44hEstudo randomizado | Tixagevimabe-cilgavimabe intramuscular pode ser benéfico para adultos não vacinados e não internados com Covid-19.
19 Jun, 2022 | 13:33hComentários:
Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID – News Medical
Comentário no Twitter
NEW—A single intramuscular tixagevimab–cilgavimab dose provided protection against progression to severe COVID-19 or death vs placebo in unvaccinated individuals
TACKLE trial from Prof Hugh Montgomery & colleagues https://t.co/M9LENFsA2C pic.twitter.com/Aon4wJsBOi
— The Lancet Respiratory Medicine (@LancetRespirMed) June 8, 2022
Inibidor de SGLT2 reduz o risco de hiperpotassemia em pacientes com insuficiência cardíaca.
19 Jun, 2022 | 13:15hEditorial: Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure
Conteúdo relacionado: Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial – European Heart Journal
Comentário no Twitter
More evidence that SGLT2i ⬇️ hyperK, this time in heart failure
Empagliflozin reduces:
– K>6.0: HR 0.62 95% CI 0.48–0.81
– Investigator reported hyperK or K binders, HR 0.82 95% CI 0.71-0.95
– Effect modified by GFR – larger in CKD
– Regardless of MRAshttps://t.co/t4T7II1G8p pic.twitter.com/RP1EUKXHyV— Brendon Neuen (@brendonneuen) June 12, 2022
Sob a licença de https://creativecommons.org/licenses/by-nc/4.0/
Estudo de coorte | Desfechos de longo prazo com o uso precoce de antipsicóticos injetáveis de ação prolongada na esquizofrenia.
19 Jun, 2022 | 13:10hLong-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia – The Journal of Clinical Psychiatry (link to abstract – $ for full-text)
Conteúdos relacionados:
Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis – The Lancet (link para o resumo – $ para o texto completo)
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link para o resumo – $ para o texto completo)
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link para o resumo – $ para o texto completo)
Revisão sistemática | Oxicodona para dor relacionada a câncer.
19 Jun, 2022 | 13:05hOxycodone for cancer‐related pain – Cochrane Library
Resumo: Oxycodone for cancer-related pain in adults – Cochrane Library